Summary : Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that…
EMA
-
-
EMAEurope
Myovant Sciences Announces European Commission Approval for ORGOVYX® (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
by adminSummary : ORGOVYX® is the first and only oral and rogend privation therapy for advanced hormone-sensitive…
-
EMA
EMA establishes a Cancer Medicines Forum to optimize Cancer Treatments in Clinical practice
by adminSummary EMA has launched the Cancer Medicines Forum (CMF) in collaboration with the European Organization…
-
In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new…